C-myc mRNA expression in epithelial ovarian carcinomas in relation to estrogen receptor status, metastatic spread, survival time, FIGO stage, and histologic grade and type

International Journal of Gynecological Pathology

Volumn 17, Issue 1, 1998, Pages 66-74

  Tanner, Berno ^a   Hengstler, J G ^b   Luch, A ^b   Meinert, R ^b   Kreutz, E ^b   Arand, M ^b   Wilkens, C ^b   Hofmann, M ^b   Oesch, F ^b   Knapstein, P G ^b   Becker, R ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NONE

Author keywords

C myc mRNA; Estrogen receptor; Metastatic spread; Ovarian cancer; Progesterone receptor; S1 nuclease assay

Indexed keywords

ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; GYNECOLOGIC CANCER; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE C MYC; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0031964162     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199801000-00012     Document Type: Article

References (33)

1. Cole MD. The myc oncogene: its role in transformation and differentiation. Ann Rev Genet 1986;20:361-84.
2. Field JK, Spandidos DA. The role of ras and myc oncogenes in human solid tumors and their relevance in diagnosis and prognosis. Anticancer Res 1990;10:1-22.
3. Bourhis J, Le MG, Barrois M, Gerbaulet A, Jeannel D, Duvillard P, Le Doussal V, Chassagna, D, Riou G. Prognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix. J Clin Oncol 1990;8:1789-96.
4. Ocadiz R, Sauceda R, Cruz M, Graeff A, Gariglio, P. High correlation between molecular alterations of the c-myc oncogene and carcinoma of the uterine cervix. Cancer Res 1987;47:4173-7.
5. Greil R, Fasching B, Loidl P, Huber H. Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis. Blood 1991;78:180-91.
6. Care A, Cianetti L, Giampaolo A, Sposi NM, Zappavigna V, Mavillio F, Alimena G, Anmadori S, Mandelli F, Peschle C. Translocation of c-myc into the immunoglobulin heavy-chain locus in human acute B-cell leukemia. A molecular analysis. EMBO J 1986;5:905-11.
7. Prins J, DeVries EGE, Mulder NH. The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res 1993;13:1373-86.
8. Berns EMJJ, Klijn JGM, Van Putten WLJ, Van Staveren IL, Portengen H, Foekens JA. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 1992;52:1107-13.
9. Tashiro H, Miyazaki K, Okamura H, Iwai A, Fukomoto M. c-myc overexpression in human primary ovarian tumours: its relevance to tumour progression. Int J Cancer 1992;50:828-33.
10. Sasano H, Nagura H, Silverberg SG. Immunolocalization of c-myc oncoprotein in mucinous and serous adenocarcinomas of the ovary. Hum Pathol 1992;5:491-5.
11. Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM, Miller D. c-myc amplification in ovarian cancer. Gynecol Oncol 1990; 38:340-2.
12. Bauknecht T, Birmelin G, Kommoss F. Clinical significance of oncogenes and growth factors in ovarian carcinomas. J Steroid Biochem Mol Biol 1990;37:855-62.
13. Garte SJ. The myc oncogene in tumor progression. Crit Rev Oncog 1993;4:435-49.
14. Chien CH, Wang FF, Hamilton TC. Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells. Mol Cell Endocrinol 1994;99:11-9.
15. Volm M, Koomagi R, Kaufmann M, Mattern J, Stammler G. Microvessel density, expression of proto-oncogenes, resistance-related proteins and incidence of metastasis in primary ovarian carcinomas. Clin Exp Metastasis 1996;14:209-14.
16. World Health Organization. International Classification of Tumours No. 9. WHO: Geneva 1973.
17. Czernobilsky B. Common epithelial tumors of the ovary. In: Kurman RJ (ed). Blaustein's Pathology of the Female Genital Tract. Springer Verlag, New York 1987:560-607.
18. FIGO. Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 1971;50:1-7.
19. Beck T, Weikel W, Brumm C, Wilkens C, Pollow K. Knapstein PG. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): Prognostic usefulness and comparison with the biochemical radioactive-ligund-binding assay (DCC). Gyn Oncol 1994;53:220-7.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol chloroform extraction. Anal Biochem 1987;162:156-9.
21. Tanner B, Kreutz E, Weikel W, Meinen R, Oesch F, Knapstein PG, Becker R. Prognostic significance of c-erbB-2 mRNA in ovarian carcinoma. Gynecol Oncol 1996;62:268-77.
22. Tanner B, Hengstler JG, Laubscher S, Meinert R, Weikel W, Oesch F, Knapstein PG, Becker R. MDM2 mRNA expression is associated with survival in ovarian cancer. Int J Cancer 1997; (in press).
23. Myers RM, Larin Z, Maniatis T. Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes. Science 1985;230:1242-6.
24. Krieg PA, Melton DA. Functional messenger RNA's are produced by SP6 transcription of cloned cDNA's. Nucleic Acids Res 1984; 12:7057-70.
25. Kalbfleisch JD, Prentice RC. The Statistical Analysis of Failure Time Data. New York: Wiley, 1980.
26. SAS Institute Inc. SAS/STAT User's Guide. Version 6. 1990:1 and 2;1.
27. Watson JV, Curling OM, Munn CF, Hudson CN. Oncogene expression in ovarian cancer: a pilot study of c-myc oncoprotein in serous papillary ovarian cancer. Gynecol Oncol 1987;28:137-50.
28. Volm M, Koomagi R, Kaufmann M, Mattern J, Stammler G. Microvessel density, expression of proto-oncogenes, resistance-related proteins and incidence of metastases in primary ovarian carcinomas. Clin Exp Metastasis 1996;14:209-14.
29. Tanner B, Friedberg T, Mitze M, Beck T, Oesch F, Knapstein PG. c-erbB-2-oncogene expression in breast carcinoma: analysis by S1 nuclease protection assay and immunohistochemistry in relation to clinical parameters. Gynecol Oncol 1992;47:228-33.
30. Aure JC, Høeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma: Long-term follow-up of 990 cases. Obstet Gynecol 1971;37:1-9.
31. Guthrie D, Davy MLJ, Philips PR. A study of 656 patients with "early" ovarian cancer. Gynecol Oncol 1984;17:363-9.
32. Richardson GS, Scully RE, Nikrui N, Nelson JH Jr. Common epithelial cancer of the ovary. N Engl J Med 1985;312:415-24.
33. Singleton TP, Perrone T, Oakley G, Niehans GA, Carson L, Cha SS, Strickler JG. Activation of c-erbB-2 and prognosis in ovarian carcinoma. Cancer 1994;73:1460-6.